CD1C and neoplasm: Increased levels of myeloid DC subsets were noted relative to other myeloid subsets in patients experiencing tumor regression, and high levels of CD1c/BDCA-1(+) MDSC were predictive of tumor regression and improved progression free survival (van Cruijsen et al., 2008), suggesting that sunitinib may play an immunomodulatory role in the tumor bearing host.